Table 2.
Treatment administration
| Sunitinib (N = 238) | Capecitabine (N = 240) | |
|---|---|---|
| Median number of cycles started (range) | 4 (1–27) | 5 (1–40) |
| Median number of days on drug (range)a | 61 (1–485) | 61 (4–540) |
| Dosing interruptions,bn (%) | 124 (52) | 110 (46) |
| Median average duration (range), days | 10 (3–43) | 7 (3–35) |
| Dosing delays, n (%) | NA | 109 (45) |
| Median average duration (range), days | NA | 7 (3–33) |
| Dose reductions,cn (%) | 66 (28) | 84 (35) |
| Median relative dose intensity (range), % | 73 (5–114) | 95 (19–124) |
NA: not applicable (only dosing interruptions are possible on a CDD schedule as the study drug is administered every day)
aTotal number of dosing days from first to last day of treatment
bDefined as ≥3 consecutive days on which treatment was not given
cDefined as any dose ≥10% lower than the previous dose